Aigen Investment Management LP Invests $523,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Aigen Investment Management LP purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, Holdings Channel reports. The firm purchased 3,330 shares of the company’s stock, valued at approximately $523,000.

A number of other institutional investors and hedge funds also recently modified their holdings of TMDX. International Assets Investment Management LLC bought a new stake in TransMedics Group in the second quarter worth about $47,000. USA Financial Formulas purchased a new position in TransMedics Group in the third quarter valued at approximately $55,000. J.Safra Asset Management Corp grew its holdings in TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC grew its holdings in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the period. Finally, Farther Finance Advisors LLC increased its position in TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after buying an additional 316 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TMDX shares. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target on shares of TransMedics Group in a research note on Tuesday, October 29th. Oppenheimer lowered their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Robert W. Baird dropped their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. cut their price target on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group currently has a consensus rating of “Buy” and an average price target of $144.80.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $88.36 on Friday. The stock has a market cap of $2.97 billion, a P/E ratio of 94.00 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business’s 50-day moving average price is $127.92 and its two-hundred day moving average price is $139.56. TransMedics Group, Inc. has a twelve month low of $63.85 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. As a group, equities analysts predict that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Insider Activity

In other news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. This represents a 12.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,958 shares of company stock worth $5,230,528. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.